About the Role
This desk-based (non wet-lab) position will focus on disease strategy and preclinical design in the context of an early-stage AI drug discovery company. The role will drive and support both our top-down strategy, and our bottom-up preclinical experimental design, through: (1) market and target indication prioritisation; and (2) designing drug discovery projects. The position may also offer outstanding opportunities to lead clinical programmes, IND applications, and ultimately bring a novel, precision-ready, therapeutic to the clinic.
It is ideally suited for a motivated scientist who is passionate about the fusion of pharmaceuticals and technology, and enjoys applying their experimental biology background to commercial strategy.
Top-down strategy: Support the prioritisation of mechanism, disease areas, targets, route of administration and the delivery technology.
Conduct primary market research through interviews with clinicians, patients, Pharma and other stakeholders.
Create target dossiers, which includes:
Literature reviews using Protein Atlas, Geoterms and KEGG pathway analysis
Patent landscape evaluation, drug tractability, target-disease biology and differentiated efficacies.
Supporting bottom-up experimental design: Support the design of in-vitro and in-cellulo proof of concept experiments for aptamer-based protein inhibitors and degraders, aptamer-based delivery systems (LNPs and ADCs).
Analyse, interpret, and organise results to present to colleagues in regular internal research meetings, as well as external national/international and investor meetings.
Suggest your own ideas and present strategy proposals to the senior management, and clinical advisory board.
Assist in the writing of scientific articles, whitepapers and patents.
Collaborate with the internal R&D AI team, as well as our ongoing relationships with industry partners, academic partners, CROs/CDMOs, clinicians, patients, investors, and our advisory board.
Must have obtained (or be awaiting viva following the completion of your thesis) a Ph.D degree or Masters degree in Chemical Biology or a related field in Life Sciences, such as Biochemistry, Molecular Biology, Cell Biology or Pharmacology.
4+ years industry experience (private small/startup or medium to large pharma).
Industry drug discovery and development experience and, as a bonus, experience with one of: targeted protein degraders, oligonucleotides, aptamers, other biologics, ADCs or small molecule inhibitors.
An entrepreneurial mindset to problem solving.
English language speaking, listening and writing fluency.
Hands-on experience with a range of biologics-based assays and techniques that evaluate in-vitro cytotoxicity, activity, internalisation and dose-response efficacy (such as ELISA/ELONA, MTT, western blot, EMSA).
Experienced in high-throughput in-cellulo screening of drug assets.
Have taken a drug to IND submission (Ph1 clinical trials).
Publications in major scientific journals.
About the Company
Read more about PentaBind, our culture and what to expect via the button below.